Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053625 · ClinicalTrials.gov registry record · Phase 3
Deep Brain Stimulation for Parkinson's Disease Trial
A Phase 3 study of Parkinson's Disease, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
- 2
- Study locations
NCT00053625 is a Phase 3 study of Parkinson's Disease that has completed, run by University of Minnesota. The registered enrollment target is 123 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (81% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00053625, a Phase 3 study of Parkinson's Disease, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.
Conditions Studied
Interventions
- PROCEDURE deep brain stimulation
Study Locations (2)
Georgia
- Emory University School of Medicine, Neurology Department - Atlanta
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 1999-06 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00053625
The ClinicalTrials.gov registry entry for NCT00053625 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (81% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which deep brain stimulation is the first listed.
NCT00053625 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT00053625 about?
NCT00053625 is a clinical study titled "Deep Brain Stimulation for Parkinson's Disease Trial". The purpose of this trial is to evaluate the effect of deep brain stimulation in the the globus pallidus (Gpi) and the subthalamic nucleus (STN) on motor, neuropsychological and psychiatric function, and quality of life in patients with Parkinson's disease.
What is the current status of trial NCT00053625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 1999-06. Estimated completion is 2009-06.
What conditions does trial NCT00053625 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00053625?
The interventions under investigation include: deep brain stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT00053625?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00053625 being conducted?
This trial has 2 study locations across Georgia, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
-
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.